Last checked at 8 Apr 2010 09:26
| For Immediate Release | 8 April 2010 |
ImmuPharma PLC
("ImmuPharma")
ImmuPharma awarded Best Drug Development Company in Europe Award
ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.
This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.
- Ends -
For further information please contact:
| ImmuPharma PLC | +44 20 7152 4080 |
| Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman |
|
|
|
|
| Buchanan Communications | +44 20 7466 5000 |
| Lisa Baderoon George Prassas |
|
|
|
|
| Panmure Gordon & Co Andrew Burnett Rakesh Sharma | +44 151 243 0963 |
|
|
|
| Noble & Company Limited | +44 20 7763 2200 |
| James Bromhead
|
|
Notes to Editors:
About ImmuPharma PLC
ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders.
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date.
The company also has a strong proprietary and collaborative drug development pipeline.